MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Heron Therapeutics Inc

Fechado

SetorSaúde

2.17 -2.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.17

Máximo

2.23

Indicadores-chave

By Trading Economics

Rendimento

-1M

2.6M

Vendas

-1.9M

39M

Margem de lucro

6.773

Funcionários

122

EBITDA

-5M

3.7M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+143.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-16M

336M

Abertura anterior

4.42

Fecho anterior

2.17

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de jul. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FCC Approves U.S. Cellular Sale to T-Mobile

11 de jul. de 2025, 17:28 UTC

Grandes Movimentos do Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 de jul. de 2025, 16:57 UTC

Ganhos

BASF Cuts Outlook on Global Economy Uncertainty

11 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 de jul. de 2025, 19:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 de jul. de 2025, 19:45 UTC

Conversa de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 de jul. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 de jul. de 2025, 18:18 UTC

Conversa de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 de jul. de 2025, 17:35 UTC

Conversa de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 de jul. de 2025, 16:53 UTC

Conversa de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 de jul. de 2025, 16:42 UTC

Ganhos

BASF Cuts Outlook on Global Economic Uncertainty

11 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 de jul. de 2025, 16:05 UTC

Ganhos

BASF Will Publish Half-Year Results on July 30

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 de jul. de 2025, 16:03 UTC

Ganhos

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 de jul. de 2025, 16:02 UTC

Ganhos

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 de jul. de 2025, 16:01 UTC

Ganhos

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 de jul. de 2025, 16:00 UTC

Ganhos

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 de jul. de 2025, 15:59 UTC

Ganhos

BASF Cuts 2025 Earnings View

11 de jul. de 2025, 15:58 UTC

Ganhos

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 de jul. de 2025, 15:57 UTC

Ganhos

BASF 2Q EBIT Before Special Items EUR810M

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF 2Q Sales Fell 2.1% on Year

11 de jul. de 2025, 15:53 UTC

Ganhos

BASF 2Q Sales EUR15.77B

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF: This Was in Line With Consensus Estimates

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF 2Q Ebitda Before Special Items EUR1.77B

11 de jul. de 2025, 15:49 UTC

Ganhos

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 de jul. de 2025, 15:41 UTC

Conversa de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

143.24% parte superior

Previsão para 12 meses

Média 5.4 USD  143.24%

Máximo 9 USD

Mínimo 2 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

4

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.0001 / 2.42Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.